No evidence for a major role of polymorphisms during bupropion treatment

Obesity

Volumn 14, Issue 11, 2006, Pages 1863-1867

  Hu, Jianfang ^a   Redden, David T ^a   Berrettini, Wade H ^b   Shields, Peter G ^c   Restine, Stephanie L ^d   Pinto, Angela ^b   Lerman, Caryn ^b   Allison, David B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bupropion; Gene; Smoking cessation; Weight gain

Indexed keywords

EID: 33846269664     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2006.215     Document Type: Article

References (18)

1. Grunberg NE, Greenwood MR, Collins F, et al. National working conference on smoking and body weight: Task Force 1-mechanisms relevant to the relations between cigarette smoking and body weight. Health Psychol. 1992;11(Suppl):4-9.
2. Swan GE, Carmelli D. Characteristics associated with excessive weight gain after smoking cessation in men. Am J Public Health. 1995;85:73-7.
3. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6:159-66.
4. Martinez-Raga J, Keaney F, Sutherland G, Perez-Galvez B, Strang J. Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. Addict Biol. 2003;8:13-21.
5. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049-56.
6. Lerman C, Berrettini W, Pinto A, et al. Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berl). 2004;174:571-7.
7. Arinami K, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet. 1997;6:577-82.
8. Lerman C, Jepson C, Wileyto EP, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology. 2006;31:231-42.
9. Lerman C, Shields PG, Wileyto AP, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 2003;22:541-8.
10. Tworoger SS, Chubak J, Aiello EJ, et al. The effect of CYP19 and COMT polymorphisms on exercise-induced fat loss in postmenopausal women. Obes Res. 2004;12:972-81.
11. Li MD. The genetics of smoking related behavior: a brief review. Am J Med Sci. 2003;326:168-73.
12. Allison DB, Pietrobelli A, Faith MS, Fontaine KR, Gropp E, Fernández JR. Genetic influences on obesity. In: Eckel R, ed. Obesity: Mechanisms and Clinical Management. New York: Elsevier; 2003, pp. 31-74.
13. Lerman C, Shields PG, Wileyto EP, et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics. 2002;12:627-34.
14. Lerman C, Roth D, Kaufmann V, et al. Mediating mechanism for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 2000;67:219-23.
15. Tell GS, Jeffery RW, Kramer FM, Snell MK. Can self-reported body weight be used to evaluate long-term follow-up of a weight loss program? J Am Diet Assoc. 1987;87:1198-201.
16. Lerman C, Caporaso NE, Audrain J, et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol. 1999;18:14-20.
17. Allison DB, Neale MC. Joint tests of linkage and association for quantitative traits. Theor Popul Biol 2001;60:239-51.
18. Pritchard JK, Donnelly P. Case-control studies of association in structured or admixed populations. Theor Popul Biol. 2001;60:227-37.